Tech war: Huawei’s computing cluster to power AI projects, challenge US platforms


The Atlas 950 and Atlas 960 SuperPoDs, as well as the Atlas 950 and Atlas 960 SuperClusters, are expected to help the Shenzhen-based firm “circumvent the limitations in China’s chip manufacturing process”, Huawei deputy chairman Eric Xu Zhijun, who serves as the privately held company’s rotating chairman from April to September, told Chinese media on the sidelines of the Huawei Connect 2025 conference in Shanghai last week.

By the fourth quarter of next year, Huawei plans to release the Atlas 950 SuperPoD that is powered by 8,192 Ascend neural processing unit (NPU) cards – optimised for AI neural networks and machine learning tasks and applications.

The Atlas 960 SuperPoD, powered by up to 15,488 Ascend 960 NPU cards, will be available by the end of 2027, according to Huawei.

The Atlas 950 and 960 SuperClusters are large-scale computing clusters that comprise multiple Huawei SuperPoDs. The Atlas 950 SuperCluster, available by the end of 2026, will have more than 500,000 Ascend NPUs, while the Atlas 960 SuperCluster will have more than 1 million Ascend NPUs.

With the “world’s most powerful” SuperPoDs and SuperClusters, Huawei has what it takes to provide “abundant computing power for ongoing, rapid advancements in AI, both now and in the future,” Xu said.

Huawei deputy chairman Eric Xu Zhijun speaks at the opening of the Huawei Connect 2025 conference last Thursday. Photo: Handout
Huawei deputy chairman Eric Xu Zhijun speaks at the opening of the Huawei Connect 2025 conference last Thursday. Photo: Handout
  • Related Posts

    China issues new safety rules for OpenClaw. Here are the dos and don’ts

    A unit of China’s Ministry of Industry and Information Technology (MIIT) has issued guidelines on best practices and prohibitions for adopting and using OpenClaw, the popular artificial intelligence agent that…

    Continue reading
    Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

    Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *